Daniel Yang, MD
Radiation Oncology · New Haven, CTNPI 1750818928
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,483 of the $2,404 with a category attached, or 61.7%. Regeneron accounts for 65.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,421 and has fallen 94.2% since, to $82 in 2025.
Across 12 payments — averaging $200.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2K
- Telix Pharmaceuticals$214
- Reflexion Medical, Inc.$213
- Angiodynamics, Inc.$143
- Blue Earth Diagnostics$112
- Johnson & Johnson$94
- plus $63 from 2 others
What the payments were for
- Travel & lodging$1,48362%
- Food & beverage$92138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 4 | $1,565 |
| Telix Pharmaceuticals | 2 | $214 |
| Reflexion Medical, Inc. | 1 | $213 |
| Angiodynamics, Inc. | 1 | $143 |
| Blue Earth Diagnostics | 1 | $112 |
| Johnson & Johnson | 1 | $94 |
| Progenics Pharmaceuticals, Inc. | 1 | $44 |
| Boston Scientific | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REFLEXION MEDICAL RADIOTHERAPY SYSTEM$213
- ILLUCCIX$151
- Nanoknife$143
- POSLUMA$112
How this compares
$2,404 in reported general payments places this provider in the 80th percentile of 74 radiation oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 98 | $1,515 |
| Bicalutamide | 25 | $441 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $212 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in New Haven
- Roy DeckerNew Haven$111K
- Ranjit BindraNew Haven$64K
- Henry ParkNew Haven$25K
- Zain HusainNew Haven$14K
- Meena Savur MoranNew Haven$4K
- Melissa YoungNew Haven$2K
- Stephen ShiaoNew Haven$2K
- Christin KnowltonNew Haven$2K
- Susan HigginsNew Haven$2K
- Kevin duNew Haven$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.